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Although the receptors for vascular endothelial growth factor
(VEGF) exert their effects on vasculogenesis and angiogenesis
through receptors located on endothelial cells, recent studies
have shown that these receptors are also present on renal
tubular epithelial cells. We investigated the role of VEGF on
increased tubule cell proliferation in the Han:SPRD
heterozygous (Cy/þ ) rat model of polycystic kidney disease.
The levels of VEGF in the kidneys and the serum, and the
expression of the two receptors on tubules were increased in
Cy/þ rats. These rats were given ribozymes that specifically
inhibited VEGFR1 and VEGFR2 mRNA expression. Tubule cell
proliferation within the cysts was significantly decreased in
the ribozyme-treated animals leading to decreased
cystogenesis, blunted renal enlargement, and prevented the
loss of renal function. Our studies show that inhibition of
VEGF function may be an important therapeutic option to
delay the progression of polycystic kidney disease.
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Autosomal-dominant polycystic kidney disease (ADPKD) is
the most common life-threatening hereditary disease in the
United States. ADPKD accounts for approximately 5–10% of
end-stage renal failure that requires dialysis and renal
transplantation in the United States. Currently, there is no
effective treatment for ADPKD.
Vascular endothelial growth factor (VEGF), also known as
VEGF-A, was initially described as an endothelial cell-specific
growth factor that promotes vasculogenesis, angiogenesis,
and increases vascular permeability.1–3 VEGF exerts its
biological effect through interaction with two receptor
tyrosine kinases, VEGF receptor 1 (VEGFR1, also know as
Flt-1) and VEGF receptor 2 (VEGFR2, also know as KDR/
Flk-1). VEGFRs have traditionally been described as being
expressed by endothelial cells; however, recent studies have
demonstrated that VEGFRs are also expressed on a variety of
nonendothelial cells including renal tubular epithelial cells4,5
and most cancer cells.6–11
Increased proliferation of tubular epithelial cells plays a
crucial role in cyst development and growth in ADPKD.12–15
However, the pathway(s) that mediate the increase in
proliferation are unclear. Therefore, in this study, we
investigated the role of VEGF on the increased tubular cell
proliferation, cyst formation, and enlargement in ADPKD
kidneys.
Strategies targeting VEGF and VEGFRs have been a focus
of intense research on cancer therapy over the past decade.16
A variety of agents aimed at inhibition of VEGF function has
been developed for the treatment of cancer. Ribozymes that
target either VEGFR1 or VEGFR2 mRNA have been
developed. These ribozymes are well characterized and have
been shown to specifically lower the level of VEGFR1 or
VEGFR2 mRNA in cells and significantly inhibited tumor
growth.17–19
The male heterozygous (Cy/þ ) Han:SPRD rat is a well-
characterized model for ADPKD and exhibits many of the
features of ADPKD in humans. The rats show cysts in their
kidney at 3 weeks of age and develop clinically detectable
polycystic kidney disease (PKD) by 8 weeks of age, as
evidenced by a doubling of the two kidney/total body weight
ratio (2K/TBW %) and renal failure. In this study, we
investigated the VEGF and VEGFRs levels in Cy/þ kidneys
and have demonstrated that the levels of VEGF in Cy/þ
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kidneys and serum of Cy/þ rats, and the expression of
VEGFR1 and VEGFR2 in tubular epithelial cells in Cy/þ
kidneys are significantly increased compared to normal
kidneys.
To investigate whether the increased proliferation of
tubular epithelial cells in Cy/þ kidney was mediated by
VEGF, we treated male Cy/þ rats with VEGFR1 or VEGFR2
ribozymes from 3 to 8 weeks of age and investigated the
impact of these treatments on tubular cell proliferation, cyst
formation, and kidney function. Our study demonstrates that
inhibition of either VEGFR1 or VEGFR2 function decreases
the cyst epithelial cell proliferation and cyst growth
dramatically which is accompanied by improved kidney
function.
RESULTS
HIF-1a level is increased in polycystic kidneys
The expression of VEGF and VEGFRs are mainly regulated by
hypoxia,20–22 and a binding site for hypoxia-inducible factor-
1a (HIF-1a) had been identified in the VEGF and VEGFR1
promoters.23,24 Therefore, a local hypoxic environment may
be present in polycystic kidneys due to the cyst expansion. To
investigate whether a local hypoxic environment is present in
polycystic kidneys, we examined the level of HIF-1a in Cy/þ
kidneys using western blot and immunohistochemical
methods. As shown in Figure 1a, HIF-1a was barely
detectable in normal (þ /þ ) kidneys, but showed a strong
band in PKD (Cy/þ ) kidneys on western blot analysis. As
shown in Figure 1b and c, HIF-1a was undetectable in þ /þ
kidney tubular cells, but showed strong nuclear staining in
tubular cells in Cy/þ kidneys.
VEGF expression is increased in polycystic kidneys
To investigate the role of VEGF on the increased proliferation
of cystic tubular epithelial cells, we examined renal VEGF
levels in 4-week-old þ /þ , Cy/þ , and Cy/Cy rats. As VEGF
is a secretion protein, we also examined VEGF levels in serum
and cyst fluid in these rats. As shown in Figure 2a, kidney
VEGF level increased significantly in Cy/þ and Cy/Cy rats
compared to þ /þ rats (Po0.01, Po0.002, respectively). As
shown in Figure 2b, the serum VEGF in Cy/Cy rats was
increased significantly compared to þ /þ (Po0.02), and the
serum VEGF in Cy/þ rats was not significantly different
compared to þ /þ . As shown in Figure 2c, the cyst fluid
VEGF in 4-week-old Cy/Cy rats was increased significantly
compared to in 2-week-old Cy/Cy rats (Po0.02). Taken
together, these data demonstrate that the production of
VEGF increased in Cy/þ and Cy/Cy kidneys compared to
their þ /þ littermates.
VEGFR1 and VEGFR2 expression is increased in renal tubular
epithelial cells in polycystic kidneys
Next, we examined the expression of VEGFR1 and VEGFR2
in tubular epithelial cells in Cy/þ kidneys using immuno-
histochemistry. Tubular cells in þ /þ kidneys express low
level of VEGFR1 (Figure 3a and d) and VEGFR2 (Figure 4a
and d) in both cortex and medulla. However, the tubular cells
in Cy/þ kidneys had a very strong VEGFR1 (Figure 3b and
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Figure 1 | HIF-1a expression increased in Cy/þ kidneys. (a) Western blot analysis of HIF-1a protein expression in þ /þ and Cy/þ kidneys.
Actin was analyzed in identical samples and used as loading control. (b and c) Immunohistochemical staining of HIF-1a (red staining) in
þ /þ and Cy/þ kidneys. HIF-1a was not detectable in the tubular cells in þ /þ kidney in b. Intense nuclear staining of HIF-1a was detected
in the tubular cells in Cy/þ kidney (arrows).
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Figure 2 | VEGF levels (sandwich enzyme immunoassay). VEGF levels in 4-week-old þ /þ , Cy/þ , and Cy/Cy rat (a) kidney, (b) serum,
and (c) cyst fluid from 2- to 4-week-old Cy/Cy rats. Kidney tissue VEGF in Cy/þ and Cy/Cy was increased compared with þ /þ . *Po0.01 vs
þ /þ , **Po0.002 vs þ /þ . Serum VEGF in Cy/Cy was increased compared with þ /þ . ***Po0.002 vs þ /þ . Cyst fluid VEGF was
increased between 2 and 4 weeks in Cy/Cy rats. ****Po0.002 vs 2 weeks.
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e) and VEGFR2 (Figure 4b and e) staining in both cortex and
medulla. In addition, our immunohistochemical staining
demonstrated that both VEGFR1 and VEGFR2 are located on
the cell surface as well as in the cytoplasm. This is in
agreement with a recent report showing that a significant
pool of VEGFR2 is contained in the intracellular endosomal
storage pool.25 VEGFR2 staining was also detected in some
glomerular capillaries, small-vessel endothelial cells, and
smooth muscle cells of large blood vessels. Thus, in PKD
kidneys, both VEGFR1 and VEGFR2 expression were
significantly increased. As VEGF is expressed by tubular
cells, VEGF may stimulate tubular cell proliferation through
an autocrine loop.
Effect of VEGFR1 and VEGFR2 inhibition on renal tubular
epithelial cell proliferation
To investigate whether the increased proliferation of tubular
epithelial cells was mediated by VEGF, Cy/þ rats were
treated with VEGFR1 or VEGFR2 ribozyme. At the end of
treatment, we investigated the impact of treatment on the
following: (1) total VEGFR1 and VEGFR2 mRNA and
protein levels, (2) tubular cell VEGFR1 or VEGFR2 protein
expression, and (3) tubular cell proliferation. As shown in
Figure 5, VEGFR1 and VEGFR2 ribozyme treatment
specifically decreased VEGFR1 and VEGFR2 mRNA and
protein levels. VEGFR1 ribozyme decreased both VEGFR1
mRNA and protein levels, but did not alter VEGFR2 mRNA
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Figure 3 | Immunohistochemical detection of VEGFR1 (red staining) in tubular cells in þ /þ , Cy/þ , and VEGFR1 ribozyme-treated
Cy/þ kidneys. Tubular cells in þ /þ kidney show weak VEGFR1 staining in both (a, arrows) cortex and (d, arrows) medulla. Tubular cells in
Cy/þ kidney show strong VEGFR1 staining in (b, arrows) cortex and (e, arrows) medulla. VEGFR1 ribozyme-treated Cy/þ kidney had less
VEGFR1 staining in both (c, arrows) cortex and (f, arrows) medulla compared with control (b and e) Cy/þ kidney.
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Figure 4 | Immunohistochemical detection of VEGFR2 (red staining) in tubular cells in þ /þ , Cy/þ , and VEGFR2 ribozyme-treated
Cy/þ kidneys. Tubular cells in þ /þ kidney show very weak VEGFR2 staining in both (a) cortex and (d) medulla. Tubular cells in Cy/þ
kidney show strong VEGFR2 staining in (b, black arrows) cortex and (e, black arrows) medulla. VEGFR2 ribozyme-treated Cy/þ kidney
shows weak VEGFR2 staining in (c) cortex and (f) medulla. VEGFR2 staining was also detected in some glomeruli capillaries (white arrows) and
some small vessel endothelial cells (black star).
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and protein levels. Alternatively, VEGFR2 ribozyme de-
creased VEGFR2 mRNA and protein levels, but did not alter
VEGFR1 mRNA and protein levels. In our study, ribozyme
treatment decreased VEGFR1 or VEGFR2 mRNA levels by
approximately 50%, which is in agreement with the previous
published results using the same ribozyme.17 As shown in
Figure 3c and f and Figure 4c and f, both VEGFR1 and
VEGFR2 expressions in tubular epithelial cells decreased
significantly after treatment with VEGFR1 or VEGFR2
ribozyme. As shown in Figure 6, the number of proliferating
cell nuclear antigen (PCNA)-positive cells per cystic tubule
was decreased significantly in VEGFR1 and VEGFR2
ribozyme-treated Cy/þ kidneys compared to vehicle-treated
Cy/þ (Po0.01 vs vehicle-treated Cy/þ ). In addition, the
total PCNA protein level in ribozyme-treated Cy/þ kidneys
were decreased compared to vehicle-treated Cy/þ kidneys
(Figure 6, western blot inset). Thus, VEGF plays an
important role to increase tubular epithelial cell proliferation
in PKD kidneys.
Effect of VEGFR1 and VEGFR2 inhibition on cyst volume
density, renal enlargement, and renal function
We further investigated the effect of VEGFR1 and VEGFR2
inhibition on cyst volume density, kidney enlargement, and
renal function in PKD kidneys. Figure 7 shows a representa-
tive kidney section treated with vehicle (a), VEGFR1
ribozyme (b), and VEGFR2 ribozyme (c). As shown in
Table 1, (1) the cyst volume density in VEGFR1 or VEGFR2
ribozyme-treated Cy/þ kidney decreased significantly com-
pared to vehicle-treated Cy/þ kidney (Po0.01 and Po0.01,
respectively); (2) the two kidney/total body weight ratio (2K/
TBW %) in VEGFR1 or VEGFR2 ribozyme-treated Cy/þ
kidneys decreased significantly compared to vehicle-treated
Cy/þ kidney (Po0.05 and Po0.05, respectively); (3) the
serum creatinine and blood urea nitrogen levels in VEGFR1
ribozyme-treated and the blood urea nitrogen level in
VEGFR2 ribozyme-treated Cy/þ rats decreased significantly
compared to vehicle-treated Cy/þ kidney (Po0.05). Thus,
our data demonstrate that in PKD kidneys, VEGF plays an
important role on the cyst progression and kidney enlarge-
ment, and that inhibition of VEGF function slows the cyst
growth and improves kidney function.
To investigate whether the ribozyme treatment had any
adverse effect on the glomerular structure and function, we
also measured the urine albumin in treated PKD rats. As
shown in Table 1, the urine albumin to creatinine ratio was
not increased in both VEGFR1 and VEGFR2 ribozyme-
treated Cy/þ rats compared to vehicle-treated Cy/þ rats. In
contrast, the urine albumin to creatinine ratio was decreased
in VEGFR1-treated Cy/þ rats (Po0.05), suggesting that
inhibition VEGFR1 ribozyme function may improve protein-
uria in Cy/þ rats.
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Figure 5 | VEGFR1 and VEGFR2 ribozyme treatment specifically
reduced VEGFR1 and VEGFR2 mRNA and protein levels in Cy/þ
kidneys. (a) Reverse transcriptase PCR analysis of kidney VEGFR1 and
VEGFR2 mRNA levels in vehicle-treated and VEGFR1 or VEGFR2
ribozyme-treated Cy/þ rats. 28S was analyzed in identical samples
and used as loading control. (b) Western blot analysis of kidney
VEGFR1 and VEGFR2 protein expression in vehicle-treated and
VEGFR1 or VEGFR2 ribozyme-treated Cy/þ rats. Actin was analyzed
in identical samples and used as loading control. (c and d) Relative
VEGFR1 and VEGFR2 levels were quantitated by densitometry and
values represent the average of 3 samples7s.e. VEGFR1 and VEGFR2
levels on vehicle-treated Cy/þ were normalized to 1. *Po0.05 vs
vehicle-treated Cy/þ .
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Figure 6 | VEGF inhibition decreases proliferation in cystic
tubules in Cy/þ rats with ADPKD. (a) The number of
PCNA-positive cells per cyst was decreased significantly in
VEGFR1 and VEGFR2 ribozyme-treated Cy/þ compared with
vehicle-treated Cy/þ rats. *P and **Po0.01 vs vehicle-treated Cy/þ .
Inset: western blot analysis of PCNA protein expression (36 kDa) in
vehicle (C)-treated, VEGFR1 (R1), or VEGFR2 (R2) ribozyme-treated
Cy/þ kidneys. Representative images of the PCNA staining (red)
in (b) vehicle-treated Cy/þ , (c) VEGFR1 ribozyme-treated Cy/þ , and
(d) VEGFR2 ribozyme-treated Cy/þ rats.
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DISCUSSION
The expression of VEGF and VEGFRs has been shown to be
upregulated in several diseases including solid tumors,
diabetic retinopathy, rheumatoid arthritis, and psoriasis.26
Extensive evidence has suggested a causal role of VEGF in
these diseases through its effects as an angiogenesis factor,
growth factor, and proinflammatory cytokine.27–30 Strategies
targeting VEGF and VEGFRs have been a focus of intense
research on cancer therapy over the past decade.19 A variety
of agents aimed at inhibition of VEGF function has been
developed for the treatment of cancer.
Ribozymes are RNA enzymes that bind and cleave RNA
molecules in a sequence-specific manner. The specificity of
ribozymes results from the base paring of ribozyme sequences
with nucleotides that flank the cleavage site of the target
RNA. The VEGFR1 and VEGFR2 ribozymes specifically
cleave VEGFR1 and VEGFR2 mRNAs at the site of 4229 and
726 bp, respectively. These ribozymes are well characterized
and have been shown to specifically lower the level of
VEGFR1 or VEGFR2 mRNAs in cell culture. The ribozymes
also inhibit VEGF-stimulated proliferation and angiogenesis,
whereas the scrambled control ribozymes did not show any of
these effects.17–19
Beside the full-length VEGFR1, a natural soluble form of
VEGFR1 (sVEGFR1) has been identified.31,32 As sVEGFR1
contains the first 1968 bp of full-length VEGFR1, the
VEGFR1 ribozyme we used does not cleave sVEGFR1 mRNA.
We have analyzed the sVEGFR1 expression in both R1
ribozyme and vehicle-treated kidneys and confirmed that R1
ribozyme treatment did not alter sVEGFR1 levels (data not
shown).
The R1 and R2 ribozymes used in this study are resistant
to nuclease degradation in vivo, but they could be eliminated
from kidney. The pharmacokinetic study has shown that the
elimination half-time of subcutaneous administration of
300 mg per m2 per day (equal to 16.7 mg per kg per day in
rat) is 9.24 h.33 On the basis of murine models, the minimum
effective plasma concentration for antitumor activity was
0.5 mg ml1 and a phase I clinical trial has shown that
repetitive subcutaneous dosing of 300 mg per m2 day
maintained a plasma ribozyme concentration above
0.5 mg ml1. In our study, the ribozymes were administrated
with a subcutaneous osmotic minipump at a dose of 30 mg
per kg per day, which would maintain a plasma ribozyme
concentration above 0.5 mg ml1.
VEGF plays an essential role during embryonic develop-
ment. The loss of a single VEGF allele is lethal in the mouse
embryo between days 11 and 12.34 The dependence on VEGF
for normal kidney growth and survival is age-dependent.
Mice given anti-VEGF or anti-VEGFR2 antibodies during the
perinatal period manifest impaired glomerulogenesis and cyst
formation.35 In contrast, when anti-VEGF or anti-VEGFR2
antibodies were given to 2-week-old mice, no adverse effects
were noted in kidney development.35 In our study, we began
to treat Cy/þ rats at 3 weeks of age; therefore, we do not
expect adverse effects of treatment on kidney development.
There are few studies of VEGF function in PKD. Increased
angiogenesis in human PKD kidneys and expression of
VEGFR1 and VEGFR2 in these kidneys have been demons-
trated.36 VEGFR1 was found in the cells of small cystic
tubules and remnant tubules. VEGFR2 was found in
endothelial cells of small vessels surrounding cysts, as well
a b c
Figure 7 | VEGFR1 and VEGFR2 ribozyme treatment slows the cystic disease progression in Cy/þ rats. Representative kidney sections,
stained with hematoxylin–eosin, at the same magnification of (a) vehicle-treated Cy/þ , (b) VEGFR1 ribozyme-treated and (c) VEGFR2
ribozyme-treated Cy/þ rats.
Table 1 | Effects of VEGFR1 and VEGFR2 ribozyme on cystic kidney enlargement and renal function in Han:SPRD rats
+/+ vehicle +/+R1 ribozyme +/+R2 ribozyme Cy/+ vehicle Cy/+ Rl ribozyme Cy/+ R2 ribozyme
TBW(g) 26079 197 26074.2 251721 246728 26279
2KW(g) 2.170.17 1.78 2.0970.04 5.170.6 4.170.5** 4.270.4*
2KW/TBW% 0.870.04 0.9 0.8 2.170.2 1.770.2* 1.670.1*
CVD% 0 0 0 3274 1577** 1877**
BUN(mg/dl) 1871.4 11 16 3072 2471.5* 2471.8*
Cre(mg/dl) 0.470.01 0.4 0.4 0.5370.04 0.470.01* 0.4770.04
Abl/Cre 55745 — — 137781 20744* 108766
—, data not available; 2KW, two kidney weight; Alb/Cre, urine albumin/creatinine (mg g1); CVD, cyst volume density; TBW, total body weight; VEGFR, vascular endothelial
growth factor receptor.
*Po0.05 vs Cy/+ vehicle; **Po0.01 vs Cy/+ vehicle.
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as in glomerular cells and remnant tubules.36 Using a
corrosion-casting technique, Wei et al. have detected
sprouting capillaries, a hallmark of angiogenesis, in kidneys
removed from ADPKD patients indicating that angiogenesis
is present in PKD kidneys. They also demonstrated that
vascular remodeling was present in PKD kidneys, in which
the normal vascular architecture was lost and replaced by a
larger vascular network.37 ADPKD patients also have
abnormalities of the vascular system. The number of small
arteries and arterioles was greatly reduced, and the wall of
small blood vessels was markedly thickened.38–41 The large
vessels in PKD kidneys are separated, distorted, and displaced
by the cysts.36 A reduction in renal blood flow was observed
in ADPKD patients.41 Increased angiogenesis around cysts
may play a role to stimulate cyst enlargement. As VEGF is the
main mediator of angiogenesis, the VEGFR1 and VEGFR2
ribozyme treatment in our study may also inhibit angiogen-
esis. Therefore, the impact of VEGFR1 and VEGFR2
ribozyme treatment on angiogenesis in Cy/þ kidneys merits
future investigation.
In normal adult kidneys, VEGF is detected in glomerular
podocytes, distal tubules, proximal tubules, and collecting
ducts.42 High levels of VEGF expression in normal podocyte
foot processes are important in maintaining fenestrations in
glomerular vascular endothelial beds.43–47 Neutralization of
circulating VEGF by sVEGFR1 or bevacizumab, a humanized
monoclonal antibody that targets VEGF, is associated with a
significant increased risk of proteinuria.48,49 In our study,
treatment of Cy/þ rats with either VEGFR1 or VEGFR2
ribozyme for 5 weeks did not induce proteinuria. This
difference may be due to the fact that VEGFR1 or VEGFR2
ribozyme treatment decreases only approximately 50% of
VEGFR1 or VEGFR2 mRNA and protein levels as demons-
trated by our reverse transcriptase PCR and western blot
analysis (Figure 5). Our results suggest that inhibition of only
a portion of VEGF function may be beneficial in PKD
kidneys, as VEGF signaling may be required to maintain
normal kidney function. In addition, we found that the Cy/
þ rats treated with VEGFR1 ribozyme have less proteinuria
compared with control Cy/þ rats, suggesting that inhibition
of VEGFR1 function may improve kidney function in Cy/þ
rats.
As a control, we also treated þ /þ rats with either R1 or
R2 ribozymes. The blood creatinine and blood urea nitrogen
levels were not different between the vehicle and ribozyme-
treated groups (Table 1) indicating that the treatment had no
adverse effect on kidney function.
In PKD kidneys, a local hypoxic environment may be
present due to the development of a large number of cysts.
Using western blot and immunohistochemical methods, we
have shown that HIF-1a level was increased in PKD kidneys,
indicating that a hypoxic environment may stimulate HIF-1a
in PKD kidneys. As hypoxia is the main stimulus for VEGF
and VEGFRs expression, we investigated VEGF and VEGFRs
levels in PKD rats. Our study shows that VEGF levels in the
kidney and serum in 4-week-old Cy/þ and Cy/Cy rats
increased compared to wild type. VEGF is present in cyst
fluid in Cy/Cy rats, and the level increased as cystic disease
progresses from 2 to 4 weeks of age. In addition, we have
shown that both VEGFR1 and VEGFR2 are present and
upregulated in tubular epithelial cells in PKD kidney.
VEGF is a well-known mediator of angiogenesis; however,
little is known about the role of VEGF in tubular epithelial
cells. In the normal kidney, tubular cell proliferation ceases
before birth; however, in PKD kidneys, tubular cells continue
to proliferate, forming expanded tubules that become fluid-
filled cysts.50 The function of VEGF/VEGFR2 interaction on
endothelial cells has been well characterized, and it was
generally accepted that VEGFR2 is the major mediator of
VEGF function. VEGF/VEGFR1 interaction was initially
believed to play a relatively minor role in VEGF-mediated
signal transduction, as only weak autophosphorylation of
VEGFR1 was observed in response to VEGF.51 As VEGFR1
has a high affinity to VEGF, it has been suggested that
VEGFR1 might function as a decoy receptor that negatively
regulates VEGF signaling by preventing binding of VEGF to
VEGFR2.52 More recently, however, evidence has emerged
suggesting that VEGF/VEGFR1 interaction may also play an
important role in cell proliferation and migration.53,54 Our
study, therefore, investigated the role of both VEGFR1 and
VEGFR2 in the increased tubular epithelial cell proliferation
in PKD kidneys. We demonstrated that both VEGFR1 and
VEGFR2 ribozyme treatment inhibits cystic epithelial cell
proliferation, slows cyst enlargement, and improves kidney
function. Thus, our study demonstrated that both VEGF/
VEGFR1 and VEGF/VEGFR2 signaling play an important
role on the increased tubular epithelial cell proliferation in
PKD kidneys.
ADPKD is a significant cause of renal failure in adults and
there are currently no effective treatments. As variety of
agents aimed at blocking VEGF or VEGFRs are currently
being developed and used in clinical trials. Further VEGF
inhibition studies in other animal models of PKD and clinical
studies are exciting prospects.
MATERIALS AND METHODS
Animals
The study was conducted in the Han:SPRD rat model of PKD.
A colony of Han:SPRD rats were established in our animal care facility
from a litter, which was obtained from Polycystic Kidney Program at
the University of Kansas Medical Center (Kansas City, Kansas). All
experiments were performed according to protocols approved by the
University of Colorado Health Sciences Center Animal Care and Use
Committee. Rats had free access to tap water and standard rat chow.
VEGFR1 and VEGFR2 ribozyme treatments
Chemically stabilized hammerhead ribozymes that specifically target
VEGFR1 (R1 ribozyme) or VEGFR2 (R2 ribozyme) mRNA were gift
from Ribozyme Pharmaceuticals Inc. (Boulder, Colorado, USA).
R1 or R2 ribozymes and the control vehicle (phosphate-buffered saline)
were administered to 3-week-old male Cy/þ rats with an sc 14-day
Alzet Osmotic minipump (Model 1002; Durect Corporation,
Cupertino, CA, USA) at a concentration of 30 mg per kg per day.
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After 5 weeks of treatment, rats were anesthetized by intraperitoneal
injection of sodium pentobarbital (50 mg kg1 body weight), and
the blood, cyst fluid, and urine were collected. The kidneys were
weighed after removal; and the left kidney was cut longitudinally in
half and one-half was fixed in 4% paraformaldehyde in phosphate-
buffered saline for histological examinations, the other half was frozen
in liquid nitrogen and stored at 801C for later protein analysis.
Western blotting
Kidney lysates were prepared in RIPA buffer (1% Triton X-100, 1%
deoxycholate, 0.1% sodium dodecyl sulfate, 20 mM Tris, 0.16 M NaCl,
1 mM EGTA (ethylene glycol bis(b-aminoethylether)-N,N,N’,N’,-
tetraacetic acid), 1 mM EDTA, 15 mM sodium fluoride) containing
1 mM phenylmethylsulfonyl fluoride, 0.5 mg ml1 leupeptin, and
0.5mg ml1 pepstatin. Equal amounts of proteins were separated by
a 12 or 6% sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis, transferred to a polyvinylidene fluoride membrane, and blocked
with 5% non-fat dry milk in Tris-buffered saline Tween 20 (TBST)
(50 mM Tris, 150 mM NaCl, and 0.1% Tween 20, pH 7.5). The
membranes were incubated with the following primary antibodies in
2.5% non-fat milk in TBST: VEGFR1 (H-225, 1:100; Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA), VEGFR2 (C-1158, 1:100;
Santa Cruz Biotechnology), PCNA (Fl-261, 1:500; Santa Cruz
Biotechnology), and HIF-1a (NB100-134, 1:200; Novus Biologicals
Inc., Littleton, CO, USA). After washing with TBST, the membranes
were then incubated with anti-rabbit horseradish peroxidase-linked
secondary antibody (1:2000), and the immunoreactive proteins were
detected with ECL plus western blotting detection system (Amer-
sham Biosciences, Pittsburgh, PA, USA).
Enzyme immunoassay for VEGF
A sandwich enzyme immunoassay kit was used for measuring VEGF
level in serum, cyst fluid, and kidney extracts (Quantikines
MMV00; R&D Systems, Minneapolis, MN, USA). The VEGF assay
kit recognizes both the VEGF164 and VEGF120 isoforms. Kidney
protein extracts were prepared as follows: the kidney was first
homogenized in PBS containing 0.1% Triton X-100 and protease
inhibitor cocktail (Sigma, St Louis, MO, USA), followed by one
freeze thaw cycle before centrifugation at 12 000 g for 30 min. Cyst
fluid was collected from Cy/Cy kidneys with a 26G needle. Before
assay, the kidney protein extracts were diluted five times with assay
buffer, so the final Triton X-100 concentration was 0.02%. VEGF
standards were dissolved in the same buffer as kidney protein
extracts.
Immunohistochemistry
Paraffin-embedded kidney sections (5 mm) fixed in 4% paraform-
aldehyde were used to analyze tubular cell VEGFR1, VEGFR2, PCNA,
and HIF-1a. For antigen retrieval, the sections were first immersed
in heated (95–1001C) 0.1 M citrate buffer, pH 6.0 for 10 min, and
then cooled to room temperature. Nonspecific binding was blocked
with blocking buffer (2% bovine serum albumin in TBST: 10 mM
Tris/HCl, pH 7.5, 150 mM NaCl, 0.1% Tween 20). The sections were
then incubated with anti-VEGFR1 (sc-316, 1:50; Santa Cruz
Biotechnology), anti-VEGFR2 (sc-315, 1:50; Santa Cruz Biotechno-
logy), anti-PCNA antibody (sc-7907, 1:50; Santa Cruz Biotechno-
logy); and anti-HIF-1a (NB100-134, 1:100; Novus Biologicals)
antibodies. After washing with TBST, the sections were incubated
with secondary alkaline phosphatase-labeled polymer (DAKO,
Glostrup, Denmark, EnVision System K4395) and visualized with
Fast Red.
RNA isolation and reverse transcriptase PCR
Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA,
USA) following the manufacturer’s instructions. cDNA was
synthesized using SuperScript III First-strand Synthesis System
(Invitrogen, Carlsbad, CA, USA) as per the manufacturer’s
instructions. The reverse transcriptase PCR was performed using
following primers:
VEGFR1 sense primer: 50-CGTGAAGCATCGGAAGCAA-30,
VEGFR1 antisense primer: 50-ACCGAATAGCGAGCAGATTTCT-
30; VEGFR2 sense primer: 50-TTTGGCAAATACAACCCTTCAGAT-
30, VEGFR2 antisense primer: 50-ACTCTGGGA ACTGTGAGTGTC
TTG-30.
Quantitation of tubular cell proliferation
The number of PCNA-positive cells per tubule was counted by using
a Nikon Eclipse E400 microscope equipped with a digital camera
connected to SPOT ADVANCED 3.5 imaging software by an
observer blinded to the treatment modality. To avoid confusion
between non-cystic tubules and small cysts as well as potential
changes in tubular cells lining massive cysts, PCNA-positive tubular
cells were counted in ‘medium-sized cysts’ of approximately 250-mm
diameter. At least 15 areas per sample in the cortex were randomly
selected.
Quantitation of cystic development
The percentage of two kidney/total body weight ratio (2K/TBW %)
and cyst volume density was used as indicators of cyst progression.
Hematoxylin–eosin-stained kidney sections were used to determine
the cyst volume density. This is performed by a reviewer, blinded to
the identity of the rat kidney, using point counting stereology.55
Areas of the cortex at 90, 180, and 2701C from the hilum of each
section were selected to guard against field selection variation.
Blood and urine chemistries
Serum urea nitrogen level was measured using a Beckman
autoanalyzer (Beckman Instruments, Fullerton, CA, USA). Serum
and urine creatinine levels were measured using a colorimetric
detection method. Urine albumin concentration was determined by
a competitive enzyme-linked immunosorbent assay (Nephrat II,
Exocell, Philadelphia, PA, USA). Urine protein level was expressed as
the urine albumin to creatinine ratio (mg g1).
Statistical analysis
Values are expressed as mean7s.e. Non-normally distributed data
were analyzed by the non-parametric unpaired Mann–Whitney test.
Multiple group comparisons were performed using analysis of
variance with post-test according to Newman–Keuls. A P-value of
o0.05 was considered statistically significant.
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